This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stason, W. B. Articles by Chalmers, T. C. Search for Related Content PubMed PubMed Citation Articles by Stason, W. B. Articles by Chalmers, T. C. Related Collections Cardiovascular Pharmacology Chronic ischemic heart disease Epidemiology

(Hypertension. 1999;33:24-31.)
© 1999 American Heart Association, Inc.

Scientific Contributions

Safety of Nifedipine in Angina Pectoris

A Meta-Analysis

William B. Stason; Christopher H. Schmid; Donna Niedzwiecki; Gregory W. Whiting; Jean-Francois Caubet; Douglas Cory; Don Luo; Susan D. Ross; Thomas C. Chalmers¹

From the Harvard School of Public Health (W.B.S.); Tufts University/New England Medical Center (C.H.S., D.C.); MetaWorks, Inc (W.B.S., D.N., G.W.W., J-F.C., D.L., S.D.R., T.C.C.); and Tufts University (T.C.C.), Boston, Mass.

Abstract—Our objective was to compare cardiovascular event rates in patients with stable angina receiving nifedipine as monotherapy or combination therapy and in active drug controls. A MEDLARS search of published articles from 1966 to 1995 in English, French, German, Italian, or Spanish, supplemented by a manual search of bibliographies, identified 60 randomized controlled trials that met protocol criteria. Blinded articles were extracted by 2 physicians. The pooled risks of death, withdrawal, and cardiovascular event were computed and expressed as odds ratios (ORs) for all nifedipine formulations and relative to same study control drug regimens. Thirty cardiovascular events were reported in 2635 nifedipine exposures (1.14%) and 19 events in 2655 other active drug exposures (0.72%). Unadjusted ORs for nifedipine versus controls were 1.40 (95% CI, 0.56 to 3.49) for major events (death, nonfatal myocardial infarction, stroke, revascularization procedure), 1.75 (95% CI, 0.83 to 3.67) for increased angina, and 1.61 (95% CI, 0.91 to 2.87) for all events (major events plus increased angina). Episodes of increased angina were more frequent on immediate-release nifedipine (OR, 4.19 [95% CI, 1.41 to 12.49]) and on nifedipine monotherapy (OR, 2.61 [95% CI, 1.30 to 5.26]). The OR for immediate-release nifedipine was significantly higher than that for sustained-release/extended-release nifedipine (P=0.001), and the OR for nifedipine monotherapy was higher than that for nifedipine combination therapy (P=0.03). Increased risks of cardiovascular events in patients with stable angina on nifedipine were due primarily to more episodes of increased angina, confined to the immediate-release formulation and to nifedipine monotherapy.

Key Words: angina pectoris • meta-analysis • nifedipine • safety

This article has been cited by other articles:

				Authors/Task Force Members, K. Fox, M. A. A. Garcia, D. Ardissino, P. Buszman, P. G. Camici, F. Crea, C. Daly, G. De Backer, P. Hjemdahl, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology Eur. Heart J., June 1, 2006; 27(11): 1341 - 1381. [Full Text] [PDF]

				B. L. KASISKE, H. A. CHAKKERA, and J. ROEL Explained and Unexplained Ischemic Heart Disease Risk after Renal Transplantation J. Am. Soc. Nephrol., September 1, 2000; 11(9): 1735 - 1743. [Abstract] [Full Text]